Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 4/2011

01-04-2011 | Adis Drug Profile

Methylphenidate Transdermal System

In Attention-Deficit Hyperactivity Disorder in Adolescents

Author: Gillian M. Keating

Published in: CNS Drugs | Issue 4/2011

Login to get access

Abstract

Methylphenidate transdermal system uses DOT Matrix™ technology and, once applied to the skin, releases methylphenidate continuously. In the US, methylphenidate transdermal system is indicated for use in the treatment of attention-deficit hyperactivity disorder (ADHD).
According to the results of a randomized, double-blind, multicentre, 7-week trial (core trial), methylphenidate transdermal system 10–30 mg was effective in adolescents aged 13–17 years with ADHD. The mean ADHD-Rating Scale-IV (ADHD-RS-IV) total score (primary endpoint) decreased to a significantly greater extent in adolescents receiving methylphenidate transdermal system than in those receiving placebo transdermal system.
Following the core trial, adolescents could subsequently receive methylphenidate transdermal system in an extension study of ≈6 months duration. From the start of the core trial to the end of the extension study, methylphenidate transdermal system recipients demonstrated a significant reduction in the mean ADHD-RS-IV total score.
Methylphenidate transdermal system was generally well tolerated in adolescents with ADHD. The vast majority of treatment-emergent adverse events were of mild to moderate severity in both the short-term core trial and the longer-term extension study.
Literature
1.
Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007 Jul; 46(7): 894–921PubMedCrossRef
2.
Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005 Jun 1; 57(11): 1215–20PubMedCrossRef
3.
Biederman J, Faraone S, Milberger S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996 Mar; 35(3): 343–51PubMedCrossRef
4.
5.
Wilens TE, Boellner SW, López FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008 Jun; 47(6): 700–8PubMedCrossRef
6.
Anderson VR, Scott LJ. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children. Drugs 2006; 66(8): 1117–26PubMedCrossRef
7.
Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001; 40(10): 753–72PubMedCrossRef
8.
Heal DJ, Pierce DM. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 2006; 20(9): 713–38PubMedCrossRef
9.
Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999 Dec; 37(6): 457–70PubMedCrossRef
10.
Jasinski DR, González MA, Peoples KA. Human pharmacology and abuse potential of transdermal methylphenidate in adults [abstract no. NR661 plus poster]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19–24; San Diego (CA)
11.
Pierce D, Katic A, Buckwalter M, et al. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. J Clin Psychopharmacol 2010 Oct; 30(5): 554–64PubMedCrossRef
12.
González MA, Campbell D, Rubin J. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009 Jun; 19(3): 227–32PubMedCrossRef
13.
Pierce D, Dixon CM, Wigal SB, et al. Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. J Child Adolesc Psychopharmacol 2008 Aug; 18(4): 355–64PubMedCrossRef
14.
Findling RL, Turnbow J, Burnside J, et al. A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectr 2010 Jul; 15(7): 419–30PubMed
15.
Findling RL, Katic A, Rubin R, et al. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2010 Oct; 20(5): 365–75PubMedCrossRef
16.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed (text revision). Washington,DC: American Psychiatric Association, 2000
17.
Findling RL, Civil R, Madhoo M. Methylphenidate transdermal system use and quality of life in adolescents with attention-deficit/hyperactivity disorder [poster]. European Society for Child and Adolescent Psychiatry Congress; 2009 Aug 22–26; Budapest
18.
Melmed RD, Findling RL, Civil R, et al. Efficacy of the methylphenidate transdermal system in adolescents with attention-deficit/hyperactivity disorder as evaluated by clinicians and parents/legal guardians [poster]. 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16–21; San Francisco (CA)
19.
Warshaw EM, Paller AS, Fowler JF, et al. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting. Clin Ther 2008 Feb; 30(2): 326–37PubMedCrossRef
20.
Owens J, Findling R, Civil R, et al. Methylphenidate transdermal system use and sleep quality in adolescents with ADHD [abstract no. NR2-043]. 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16–21; San Francisco (CA)
Metadata
Title
Methylphenidate Transdermal System
In Attention-Deficit Hyperactivity Disorder in Adolescents
Author
Gillian M. Keating
Publication date
01-04-2011
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2011
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11206730-000000000-00000

Other articles of this Issue 4/2011

CNS Drugs 4/2011 Go to the issue

Review Article

The Role of Antipsychotics in Smoking and Smoking Cessation

Adis Drug Evaluation

Indomethacin/Prochlorperazine/Caffeine

Leading Article

Role of Corticotropin-Releasing Factor in Drug Addiction

Review Article

Optimal Frequency of Lithium Administration in the Treatment of Bipolar Disorder

Review Article

Schizoaffective Disorder